发明名称 |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
摘要 |
<p>The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.</p> |
申请公布号 |
AU2005228446(B2) |
申请公布日期 |
2007.02.22 |
申请号 |
AU20050228446 |
申请日期 |
2005.03.31 |
申请人 |
THE GENERAL HOSPITAL CORPORATION;DANA-FARBER CANCER INSTITUTE, INC. |
发明人 |
BRUCE E. JOHNSON;JEFFREY E. SETTLEMAN;JUAN GUILLERMO PAEZ;DANIEL A. HABER;PASI ANTERO JANNE;DAPHNE WINIFRED BELL;MATTHEW MEYERSON;WILLIAM R. SELLERS;RAFFAELLA SORDELLA;THOMAS J. LYNCH |
分类号 |
C12Q1/68;C12Q1/48;G01N33/574;G01N33/74 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|